The existence of an inositide-dependent nuclear signaling has been clearly shown. In this review we focused on the nuclear PI-PLC signaling activity and its downstream effects. The main isoform present in the nucleus is PI-PLC β1 and this isoform resides in the nuclear domains called speckles and colocalizes with the splicing factor SC35. PI-PLC β1 is also involved in the physiological control of the cell cycle. Moreover, acting on the cyclin D3 promoter plays a crucial role in the process of C2C12 myoblast differentiation. Finally in hematological malignancies such as high-risk MDS, the deletion of PI-PLC β1 gene has been observed. There is the likelihood that the deletion is a prognostic marker in that 66.7% MDS patients bearing the PI-PLC β1 monoallelic deletion evolved into AML. In addition the expression of nuclear PI-PLC β1 in MDS patients is modulated by the demethylating drug azacytidine. Therefore the analysis of nuclear PI-PLC-β1 appears useful for both MDS prognosis and checking of the epigenetic effect of antileukemic drugs.
Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology / Cocco L; Faenza I; Follo MY; Billi AM; Ramazzotti G; Papa V; Martelli AM; Manzoli L. - STAMPA. - (2009), pp. 2-10. [10.1016/j.advenzreg.2008.12.001]
Nuclear inositides: PI-PLC signaling in cell growth, differentiation and pathology.
COCCO, LUCIO ILDEBRANDO;FAENZA, IRENE;FOLLO, MATILDE YUNG;BILLI, ANNA MARIA;RAMAZZOTTI, GIULIA;MARTELLI, ALBERTO MARIA;MANZOLI, LUCIA
2009
Abstract
The existence of an inositide-dependent nuclear signaling has been clearly shown. In this review we focused on the nuclear PI-PLC signaling activity and its downstream effects. The main isoform present in the nucleus is PI-PLC β1 and this isoform resides in the nuclear domains called speckles and colocalizes with the splicing factor SC35. PI-PLC β1 is also involved in the physiological control of the cell cycle. Moreover, acting on the cyclin D3 promoter plays a crucial role in the process of C2C12 myoblast differentiation. Finally in hematological malignancies such as high-risk MDS, the deletion of PI-PLC β1 gene has been observed. There is the likelihood that the deletion is a prognostic marker in that 66.7% MDS patients bearing the PI-PLC β1 monoallelic deletion evolved into AML. In addition the expression of nuclear PI-PLC β1 in MDS patients is modulated by the demethylating drug azacytidine. Therefore the analysis of nuclear PI-PLC-β1 appears useful for both MDS prognosis and checking of the epigenetic effect of antileukemic drugs.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
